Comparative efficacy and safety of the trastuzumab biosimilar HLX02 versus originator trastuzumab in the neoadjuvant THP-EC regimen for early-stage HER2-positive breast cancer: a real-world study

Key Points

• This study aims to compare the efficacy and safety of the trastuzumab biosimilar HLX02 and the originator trastuzumab in early-stage HER2-positive breast cancer.
• Conducted a real-world comparison of HLX02 and trastuzumab
• Evaluated efficacy and safety in early-stage HER2-positive breast cancer using the THP-EC regimen
• Assessments included clinical outcomes and treatment-related adverse effects.
• HLX02 demonstrated equal efficacy to originator trastuzumab
• Safety profiles of HLX02 and trastuzumab were comparable
• HLX02 is suggested as a cost-effective alternative.

Abstract